Do clinical factors help to predict disease course in inflammatory bowel disease?

World Journal of Gastroenterology

Volumn 16, Issue 21, 2010, Pages 2600-2603

  Louis, Edouard ^a   Belaiche, Jacques ^a   Reenaers, Catherine ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Clinical predictors; Crohn's disease; Ulcerative colitis

Indexed keywords

BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT;

COLON RESECTION; CROHN DISEASE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INTESTINE SURGERY; ONSET AGE; PREDICTION; RECURRENCE RISK; REVIEW; SMOKING HABIT; TREATMENT OUTCOME; ULCERATIVE COLITIS; WEIGHT REDUCTION;

EID: 77953491235     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i21.2600     Document Type: Review

References (39)

1. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classifcation: changing pattern over the course of the disease. Gut 2001; 49: 777-782
2. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Infamm Bowel Dis 2002; 8: 244-250
3. Michener WM, Whelan G, Greenstreet RL, Farmer RG. Comparison of the clinical features of Crohn's disease and ulcerative colitis with onset in childhood or adolescence. Cleve Clin Q 1982; 49: 13-16
4. Hoie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, Tsianos E, Beltrami M, Odes S, Munkholm P, Vatn M, Stockbrügger RW, Moum B. Low colectomy rates in ulcer-ative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007; 132: 507-515
5. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infixi-mab maintenance treatment reduces hospitalizations, surgeries, and procedures in fstulizing Crohn's disease. Gastro-enterology 2005; 128: 862-869
6. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Sch-reiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135: 1493-1499
7. Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, Lerebours E, Cortot A, Gower-Rousseau C, Colombel JF. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008; 135: 1106-1113
8. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706
9. Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J, Moum B, Lygren I. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430-1438
10. Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Del-forge M, El Yaf F, Colombel JF, Belaiche J. Early development of stricturing or penetrating pattern in Crohn's disease is in-fuenced by disease location, number of fares, and smoking but not by NOD2/CARD15 genotype. Gut 2003; 52: 552-557
11. Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsig-mond F, Pandur T, Erdelyi Z, Gemela O, Papp J, Lakatos L. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol 2009; 15: 3504-3510
12. Henckaerts L, Van Steen K, Verstreken I, Cleynen I, Franke A, Schreiber S, Rutgeerts P, Vermeire S. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009; 7: 972-980.e2
13. Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselink van de Kruijs MA, Cilissen M, Engels LG, Van Deursen C, Hameeteman WH, Wolters FL, Russel MG, Stockbrügger RW. Infuence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009; 104: 371-383
14. Wolters FL, Russel MG, Sijbrandij J, Ambergen T, Odes S, Riis L, Langholz E, Politi P, Qasim A, Koutroubakis I, Tsianos E, Vermeire S, Freitas J, van Zeijl G, Hoie O, Bernklev T, Bel-trami M, Rodriguez D, Stockbrügger RW, Moum B. Pheno-type at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006; 55: 1124-1130
15. Chow DK, Sung JJ, Wu JC, Tsoi KK, Leong RW, Chan FK. Upper gastrointestinal tract phenotype of Crohn's disease is associated with early surgery and further hospitalization. Infamm Bowel Dis 2009; 15: 551-557
16. Hellers G, Bergstrand O, Ewerth S, Holmström B. Occurrence and outcome after primary treatment of anal fstulae in Crohn's disease. Gut 1980; 21: 525-527
17. Siproudhis L, Mortaji A, Mary JY, Juguet F, Bretagne JF, Gos-selin M. Anal lesions: any significant prognosis in Crohn's disease? Eur J Gastroenterol Hepatol 1997; 9: 239-243
18. Veloso FT, Ferreira JT, Barros L, Almeida S. Clinical outcome of Crohn's disease: analysis according to the vienna classifca-tion and clinical activity. Infamm Bowel Dis 2001; 7: 306-313
19. Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn's disease. Gastroenterology 1979; 77: 898-906
20. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231: 38-45
21. Greenstein AJ, Lachman P, Sachar DB, Springhorn J, Hei-mann T, Janowitz HD, Aufses AH Jr. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1988; 29: 588-592
22. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-656
23. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43: 948-954
24. Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, Munkholm P, Bodini P, O'Morain C, Mouzas IA, Tsianos E, Vermeire S, Monteiro E, Limonard C, Vatn M, Fornaciari G, Pereira S, Moum B, Stockbrügger RW. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 2006; 55: 510-518
25. Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 482-488
26. Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001; 120: 1093-1099
27. Brant SR, Picco MF, Achkar JP, Bayless TM, Kane SV, Brzezinski A, Nouvet FJ, Bonen D, Karban A, Dassopoulos T, Karaliukas R, Beaty TH, Hanauer SB, Duerr RH, Cho JH. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Infamm Bowel Dis 2003; 9: 281-289
28. Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J. Effects of light smoking consumption on the clinical course of Crohn's disease. Infamm Bowel Dis 2009; 15: 734-741
29. Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvan-carova M, Bernklev T, Henriksen M, Sauar J, Vatn MH, Moum B. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44: 431-440
30. Langholz E, Munkholm P, Davidsen M, Binder V. Colorec-tal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992; 103: 1444-1451
31. Devroede GJ, Taylor WF, Sauer WG, Jackman RJ, Stickler GB. Cancer risk and life expectancy of children with ulcer-ative colitis. N Engl J Med 1971; 285: 17-21
32. Ekbom A, Helmick CG, Zack M, Holmberg L, Adami HO. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 1992; 103: 954-960
33. Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, Fischer S, Vargha P, Lakatos PL. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Infamm Bowel Dis 2006; 12: 205-211
34. Jess T, Loftus EV Jr, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck CD, Tremaine WJ, Melton LJ 3rd, Munkholm P, Sandborn WJ. Risk of intestinal cancer in infam-matory bowel disease: a population-based study from olm-sted county, Minnesota. Gastroenterology 2006; 130: 1039-1046
35. Etchevers MJ, Aceituno M, García-Bosch O, Ordás I, Sans M, Ricart E, Panés J. Risk factors and characteristics of extent progression in ulcerative colitis. Infamm Bowel Dis 2009; 15: 1320-1325
36. Gower-Rousseau C, Dauchet L, Vernier-Massouille G, Tilloy E, Brazier F, Merle V, Dupas JL, Savoye G, Baldé M, Marti R, Lerebours E, Cortot A, Salomez JL, Turck D, Colombel JF. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009; 104: 2080-2088
37. Boyko EJ, Perera DR, Koepsell TD, Keane EM, Inui TS. Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol 1988; 23: 1147-1152
38. Beaugerie L, Massot N, Carbonnel F, Cattan S, Gendre JP, Cosnes J. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol 2001; 96: 2113-2116
39. Szamosi T, Banai J, Lakatos L, Czegledi Z, David G, Zsig-mond F, Pandur T, Erdelyi Z, Gemela O, Papp M, Papp J, Lakatos PL. Early azathioprine/biological therapy is associated with decreased risk for frst surgery and delays time to surgery but not reoperation in both smokers and nonsmok-ers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol 2009; Epub ahead of print